Clinical Trial · NCT06241391

Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas

Overview

As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids analogues. Among these, 18F-FDG is the most commonly used tracer due to its broader use and easy availability. However, high physiological uptake in the brain is a significant limitation. The main limitation of other tracers is the need for onsite cyclotrons for their production, making their availability difficult. So, the search for an ideal modality is still ongoing, and the latest addition to this search is a radio ligand labeled Prostate Specific Membrane Antigen (PSMA). It is a new but potentially promising radiotracer, currently showing its utility in different malignancies. Investigators, therefore, aim to identify whether Ga-68 PSMA PET-CT has better diagnostic accuracy in the detection of recurrent gliomas than conventional imaging modalities.

Sponsor

Postgraduate Institute of Medical Education and Research

Phase

N/A

Contacts

Dr.Girish Kumar Parida, MD (CONTACT)

grissh135@gmail.com

+91 9968856817

ClinicalTrials.gov

NCT06241391

Eligibility

Inclusion

  • Patients who have undergone prior treatment with tumor resection and/or radiation therapy and/or chemotherapy.
  • Clinically suspected cases of recurrence.

Exclusion

  • Patient with life threating neurological emergency